Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCentre Jean Perrin

About this trial

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.

The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.

The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

Eligibility criteria

Qualifiers

Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.

Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.

Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment

Affiliation to a social security scheme

Disqualifiers

Minor patient

Pregnant patient

Patient under guardianship or conservatorship

Patients who object to the collection of their medical/paramedical data

Trial design

Treatments tested in this trial

  • molecular analysis

Treatment groups

55 Participants
are divided into 1 treatment group

Sponsors and collaborators